Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Clover Biopharmaceuticals's PEG Ratio or its related term are showing as below:
HKSE:02197's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.885 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Clover Biopharmaceuticals (HKSE:02197) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Clover Biopharmaceuticals PEG Ratio Related Terms
Clover Biopharmaceuticals PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02197 vs VRTX, REGN, RVMD: PEG Ratio Comparison
For the Biotechnology subindustry, Clover Biopharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clover Biopharmaceuticals PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clover Biopharmaceuticals's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Clover Biopharmaceuticals's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Clover Biopharmaceuticals (HKSE:02197) has a PEG Ratio of 0.00 as of Aug. 14, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Clover Biopharmaceuticals and its competitors. According to the industry distribution chart, Clover Biopharmaceuticals ranks #999999 out of 96 companies in the Biotechnology industry.
Is Clover Biopharmaceuticals' PEG Ratio too high?
Clover Biopharmaceuticals' current PEG Ratio is 0.00. Based on the distribution chart, Clover Biopharmaceuticals ranks #999999 out of 96 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Clover Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Clover Biopharmaceuticals' PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clover Biopharmaceuticals ranks #999999 out of 96 companies for PEG Ratio. This places Clover Biopharmaceuticals in the lower half of its industry. The industry median PEG Ratio is 1.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.89, based on 96 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Clover Biopharmaceuticals and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clover Biopharmaceuticals's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clover Biopharmaceuticals stock overvalued right now?
Clover Biopharmaceuticals (HKSE:02197) has a current PEG Ratio of 0.00. The current PEG Ratio is 0.00. Clover Biopharmaceuticals' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Clover Biopharmaceuticals (HKSE:02197), the current PEG Ratio is 0.00 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to unleashing the power of vaccines to save lives and improve health around the world. The leverage the proprietary Trimer-Tag technology platform to conduct R&D for vaccines that can fulfill unmet needs, with a focus on building a respiratory vaccine franchise to reduce the burden of vaccine-preventable diseases. The Group has only one operating segment, which is the research and development, manufacturing, and commercialisation of vaccines. Geographically, the company earns revenue from Mainland China and Korea.
28GF Score
Get the complete analysis for HKSE:02197
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02197 has been successfully added to your 
